HK1245813B - Anti-cgrp antibody formulation - Google Patents
Anti-cgrp antibody formulation Download PDFInfo
- Publication number
- HK1245813B HK1245813B HK18105442.3A HK18105442A HK1245813B HK 1245813 B HK1245813 B HK 1245813B HK 18105442 A HK18105442 A HK 18105442A HK 1245813 B HK1245813 B HK 1245813B
- Authority
- HK
- Hong Kong
- Prior art keywords
- cgrp antibody
- concentration
- pharmaceutical formulation
- formulation
- seq
- Prior art date
Links
Description
The present invention is in the field of medicine. More specifically, the present invention relates to pharmaceutical formulations comprising antibodies to calcitonin gene-related peptide (CGRP). Additional aspects of the present invention relate to the pharmaceutical formulations for use in treating patients suffering from CGRP-related disorders.
CGRP is a neuropeptide secreted by the nerves of the central and peripheral nervous systems and is implicated in pain pathways. The role of CGRP in headache and migraine has been established in the art and a number of clinical studies are currently evaluating the use of anti-CGRP antibodies for the treatment of headaches and migraine. (see, for example, Dodick et al. Lancet Neurol; 13(9): 885-892 (2014)).
Liquid pharmaceutical formulations for antibodies intended for human use require the chemical and physical stability of the antibody over its extended shelf life (e.g. WO06083689 and in WO06096491 ). Chemical instability of the antibody can result from a number of chemical reactions including deamidation, racemization, hydrolysis, oxidation, beta elimination and disulfide exchange. Physical instability can result from processes such as denaturation, aggregation, precipitation, and adsorption to surfaces. Instability of the antibody can result in the formation of a polypeptide by-product or derivatives having low activity, increased toxicity, and/or increased immunogenicity, which can pose concerns about the safety and efficacy of the antibody.
The following documents are also mentioned:
- WO 2011/156324 A1 which is concerned with cGRP antibodies;
- WO 2008/071394 A1 which is concerned with an Aβ antibody parenteral formulation;
- WO 03/039485 A1 which is concerned with a stable liquid pharmaceutical formulation of IgG antibodies; and
- US 2003/138417 A1 which is concerned with a stable liquid pharmaceutical formulation of IgG antibodies.
While the possible occurrence of protein instabilities is widely appreciated, it is difficult to predict particular instability issues for a particular protein. Applicants sought to formulate an anti-CGRP antibody ( PCT/US2011/039381 ), wherein said antibody comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the amino acid sequence of said LCVR is SEQ ID NO: 1 and the amino acid sequence of said HCVR is SEQ ID NO: 2. In formulating the anti-CGRP antibody for use in therapy, applicants discovered several factors that contributed to the instability of the antibody, such as photo degradation, polymer formation during freeze-thaw, and oxidation of polysorbate-80 (PS-80) in the formulation. Therefore, a stable pharmaceutical formulation was needed to overcome at least one or more of the observed issues.
Accordingly, the present invention provides a pharmaceutical formulation comprising an anti-CGRP antibody at a concentration of 40 mg/mL to 160 mg/mL, histidine buffer at a concentration of 10 mM, sodium chloride (NaCl) at a concentration of 150 mM, PS-80 at a concentration of 0.05% (w/v), and a pH at 5.0 to 6.5, wherein the anti-CGRP antibody comprises a light chain (LC) and a heavy chain (HC), the amino acid sequence of LC given by SEQ ID NO: 3 and the amino acid sequence of HC given by SEQ ID NO: 4. More preferably, the pharmaceutical formulation comprises an anti-CGRP antibody with two LCs and two HCs, the amino acid sequence of each LC given by SEQ ID NO: 3 and the amino acid sequence of each HC given by SEQ ID NO: 4.
In one embodiment, the pharmaceutical formulation provided comprises an anti-CGRP antibody at a concentration of 50 mg/mL to 150 mg/mL, histidine buffer at a concentration of 10 mM, sodium chloride at a concentration of 150 mM, PS-80 at a concentration of 0.05% (w/v), and a pH at about 5.0 to about 6.5, wherein the anti-CGRP antibody comprises a light chain (LC) and a heavy chain (HC), the amino acid sequence of LC given by SEQ ID NO: 3 and the amino acid sequence of HC given by SEQ ID NO: 4. More preferably, the pharmaceutical formulation comprises an anti-CGRP antibody with two LCs and two HCs, the amino acid sequence of each LC given by SEQ ID NO: 3 and the amino acid sequence of each HC given by SEQ ID NO: 4.
In one embodiment, the pharmaceutical formulation provided is one comprising an anti-CGRP antibody at a concentration of 100 mg/mL to 160 mg/mL, histidine buffer at a concentration of 10 mM, NaCl at a concentration of 150 mM, PS-80 at a concentration of 0.05% (w/v), and a pH at 5.0 to 6.5, wherein the anti-CGRP antibody comprises a light chain (LC) and a heavy chain (HC), the amino acid sequence of LC given by SEQ ID NO: 3 and the amino acid sequence of HC given by SEQ ID NO: 4. More preferably, the pharmaceutical formulation comprises an anti-CGRP antibody with two LCs and two HCs, the amino acid sequence of each LC given by SEQ ID NO: 3 and the amino acid sequence of each HC given by SEQ ID NO: 4.
In a further embodiment of the present invention the pharmaceutical formulation provided is one comprising an anti-CGRP antibody in a histidine buffer, NaCl, and PS-80, wherein the concentration of anti-CGRP antibody is selected from the group consisting of about 50 mg/mL, about 100 mg/mL, about 120 mg/mL or about 150 mg/mL, histidine buffer at a concentration of 10 mM, NaCl at a concentration of 150 mM, PS-80 at a concentration of 0.05% (w/v), and a pH at 5.0 to 6.5, wherein the anti-CGRP antibody comprises a light chain (LC) and a heavy chain (HC), the amino acid sequence of LC given by SEQ ID NO: 3 and the amino acid sequence of HC given by SEQ ID NO: 4. More preferably, the pharmaceutical formulation comprises an anti-CGRP antibody with two LCs and two HCs, the amino acid sequence of each LC given by SEQ ID NO: 3 and the amino acid sequence of each HC given by SEQ ID NO: 4.
Another embodiment of the present invention also provides a pharmaceutical formulation comprising an anti-CGRP antibody in a histidine buffer, NaCl, and PS-80, wherein the concentration of anti-CGRP antibody is selected from the group consisting of about 50 mg/mL, about 100 mg/mL, about 120 mg/mL or about 150 mg/mL, histidine buffer at a concentration of 10 mM, NaCl at a concentration of 150 mM, PS-80 at a concentration of 0.05% (w/v), and a pH at 5.0 to 6.5, wherein the anti-CGRP antibody comprises a light chain (LC) and a heavy chain (HC), the amino acid sequence of LC given by SEQ ID NO: 3 and the amino acid sequence of HC given by SEQ ID NO: 4. More preferably, the pharmaceutical formulation comprises an anti-CGRP antibody with two LCs and two HCs, the amino acid sequence of each LC given by SEQ ID NO: 3 and the amino acid sequence of each HC given by SEQ ID NO: 4.
In another embodiment, the present invention also provides a pharmaceutical formulation comprising an anti-CGRP antibody in a histidine buffer, NaCl, and PS-80, wherein the concentration of anti-CGRP antibody is selected from the group consisting of about 50 mg/mL, about 100 mg/mL, about 120mg/ml or about 150 mg/mL, histidine buffer at a concentration of 10 mM, NaCl at a concentration of 150mM, PS-80 at a concentration of 0.05% (w/v), and a pH at 5.0 to 6.5, wherein the anti-CGRP antibody comprises a light chain (LC) and a heavy chain (HC), the amino acid sequence of LC given by SEQ ID NO: 3 and the amino acid sequence of HC given by SEQ ID NO: 4. More preferably, the pharmaceutical formulation comprises an anti-CGRP antibody with two LCs and two HCs, the amino acid sequence of each LC given by SEQ ID NO: 3 and the amino acid sequence of each HC given by SEQ ID NO: 4.
In another embodiment, the present invention also provides a pharmaceutical formulation comprising an anti-CGRP antibody in a histidine buffer, NaCl, and PS-80, wherein the concentration of anti-CGRP antibody is selected from the group consisting of about 50 mg/mL, about 100 mg/mL, about 120mg/ml or about 150 mg/mL, histidine buffer at a concentration of 10 mM, NaCl at a concentration of 150mM, PS-80 at a concentration of 0.05% (w/v), and a pH at 5.0 to 6.5, wherein the anti-CGRP antibody comprises a a light chain (LC) and a heavy chain (HC), the amino acid sequence of LC given by SEQ ID NO: 3 and the amino acid sequence of HC given by SEQ ID NO: 4. More preferably, the pharmaceutical formulation comprises an anti-CGRP antibody with two LCs and two HCs, the amino acid sequence of each LC given by SEQ ID NO: 3 and the amino acid sequence of each HC given by SEQ ID NO: 4.
More particularly, the present invention provides for a pharmaceutical formulation comprising an anti-CGRP antibody at a concentration of about 120 mg/mL, histidine buffer at a concentration of 10 mM, NaCl at a concentration of 150 mM, PS-80 at a concentration of 0.05% (w/v), and pH of about 5.8, wherein the anti-CGRP antibody comprises a light chain (LC) and a heavy chain (HC), the amino acid sequence of LC given by SEQ ID NO: 3 and the amino acid sequence of HC given by SEQ ID NO: 4. More preferably, the pharmaceutical formulation comprises an anti-CGRP antibody with two LCs and two HCs, the amino acid sequence of each LC given by SEQ ID NO: 3 and the amino acid sequence of each HC given by SEQ ID NO: 4.
Preferably, the concentration of the anti-CGRP antibody in the pharmaceutical composition provided is about 50 mg/mL to about 150 mg/mL. More preferably, the concentration of the anti-CGRP antibody is about 50 mg/mL, about 100 mg/mL, about 120 mg/mL, or about 150 mg/mL.
Most preferably, the pharmaceutical formulation comprises a pH of about 5.8.
Most preferably, the pharmaceutical formulation comprises an anti-CGRP antibody at a concentration in the range of about 100 mg/mL to about 150 mg/mL, histidine buffer at a concentration of 10 mM, NaCl at a concentration of 150 mM, PS-80 at a concentration of 0.05% (w/v) and a pH of about 5.8.
The present invention also provides a pharmaceutical formulation of the present invention for use in the treatment or prevention of at least one of migraine, episodic headache, chronic headache, chronic cluster headache, and episodic cluster headache. A patient in need thereof is administered a therapeutically effective amount of a pharmaceutical formulation of the present invention. According to some embodiments, the present invention provides a pharmaceutical formulation of the present invention for use in a method of treating or preventing chronic and episodic cluster headaches comprising administering to a patient in need thereof a dose of 300 mg of an anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition. Further embodiments provide a pharmaceutical formulation of the present invention for use in method of treating or preventing chronic and episodic cluster headaches comprising administering to a patient in need thereof a dose of 360 mg of an anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition. In other embodiments, the present invention provides a pharmaceutical formulation of the present invention for use in a method of treating or preventing chronic and episodic migraines comprising administering to a patient in need thereof a dose of 120 mg of an anti-CGRP antibody. Further embodiments provide the pharmaceutical formulation of the present invention for use in a method of treating or preventing chronic and episodic migraine comprising administering to a patient in need thereof a dose of 240 mg of an anti-CGRP antibody. Another embodiment provides a pharmaceutical formulation of the present invention for use in a method of treating or preventing chronic and episodic migraine comprising administering to a patient in need thereof an initial loading dose of 240 mg of an anti-CGRP antibody followed by a monthly maintenance dose of 120 mg of an anti-CGRP antibody. Preferably, the dose is administered at weekly, semi-monthly, monthly or quarterly intervals. More preferably, the administration is monthly.
In another embodiment, the present invention also provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent cluster headache in a patient in need by administering a monthly subcutaneous dose of 300mg of an anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition, wherein the anti-CGRP antibody binds to an epitope comprising amino acids VTHRLAGLLSR of SEQ ID NO: 7. In a further embodiment, the present invention provides a pharmaceutical formulation of the present invention for use in method to treat or prevent episodic migraine in a patient in need by administering a monthly subcutaneous dose of 120mg of an anti-CGRP antibody in the pharmaceutical formulation Preferably, the pharmaceutical formulation has a pH of about 5.8. In another embodiment, the present invention also provides a pharmaceutical formulation of the present invention for use in method to treat or prevent cluster headache in a patient in need by administering a monthly subcutaneous dose of 300mg of an anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition. Preferably, the pharmaceutical formulation has a pH of about 5.8.
In another embodiment, the present invention also provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent cluster headache in a patient in need thereof by administering a monthly dose of 300 mg of an anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition. In a particular embodiment, the anti-CGRP antibody is in a pharmaceutical composition of the present invention comprising a histidine buffer at a pH of about 5.5-6.1. Preferably the pharmaceutical composition has a pH of about 5.7-6.0. More preferably, the pharmaceutical composition has a pH of about 5.8.
In another particular embodiment, the present invention also provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent cluster headache in a patient in need thereof by administering a monthly dose of 300mg of an anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition More preferably, the anti-CGRP antibody is in a pharmaceutical composition of the invention at a pH of about 5.7-6.0. Most preferably, the anti-CGRP antibody is in a pharmaceutical composition at a pH of about 5.8.
In another particular embodiment, the present invention also provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent cluster headache in a patient in need thereof by administering a monthly dose of 300mg of an anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition. More preferably, the anti-CGRP antibody is in a pharmaceutical composition of the present invention at a pH of about 5.7-6.0. Most preferably, the anti-CGRP antibody is in a pharmaceutical composition of the present invention at a pH of about 5.8.
In a further embodiment, the present invention provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent episodic migraine in a patient in need by administering a monthly subcutaneous dose of 120mg of an anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition, wherein the anti-CGRP antibody binds to an epitope comprising amino acids VTHRLAGLLSR of SEQ ID NO: 7. In a further embodiment, the present invention provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent episodic migraine in a patient in need by administering a monthly subcutaneous dose of 120mg of an anti-CGRP antibody in the pharmaceutical formulation. Preferably, the anti-CGRP antibody is in a pharmaceutical formulation of the present invention having a pH of about 5.8. In a further embodiment, the present invention provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent episodic migraine in a patient in need by administering a monthly subcutaneous dose of 120mg of an anti-CGRP, wherein the anti-CGRP antibody is in the pharmaceutical composition. Preferably, the anti-CGRP antibody is in a pharmaceutical formulation of the present invention at a pH of about 5.8.
In another embodiment the present invention provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent episodic migraine in a patient in need thereof by administering a monthly dose of 120 mg of an anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition of the present invention. In a particular embodiment, the anti-CGRP antibody is in a pharmaceutical composition of the present invention comprising a histidine buffer at a pH of about 5.5-6.1. Preferably the pharmaceutical composition has a pH of about 5.7-6.0. More preferably, the pharmaceutical composition has a pH of about 5.8.
In another particular embodiment, the present invention provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent episodic migraine in a patient in need thereof by administering a monthly dose of 120 mg of an anti-CGRP antibody, wherein the anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition More preferably, the anti-CGRP antibody is in a pharmaceutical composition at a pH of about 5.7-6.0. Most preferably, the anti-CGRP antibody is in a pharmaceutical composition at a pH of about 5.8.
In another particular embodiment the present invention provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent episodic migraine in a patient in need by administering a monthly dose of 120 mg of an anti-CGRP antibody, wherein the anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition More preferably, the anti-CGRP antibody is in a pharmaceutical composition at a pH of about 5.7-6.0. Most preferably, the anti-CGRP antibody is in a pharmaceutical composition at a pH of about 5.8.
In another embodiment the present invention provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent chronic migraine in a patient in need thereof by administering a monthly dose of 120 mg of an anti-CGRP antibody, wherein the anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition. In a particular embodiment, the anti-CGRP antibody is in a pharmaceutical composition comprising a histidine buffer at a pH of about 5.5-6.1. Preferably the pharmaceutical composition has a pH of about 5.7-6.0. More preferably, the pharmaceutical composition has a pH of about 5.8.
In another particular embodiment, the present invention provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent chronic migraine in a patient in need by administering a monthly dose of 120 mg of an anti-CGRP antibody, wherein the anti-CGRP antibody, wherein the anti-CGRP antibody is in the pharmaceutical composition,. More preferably, the anti-CGRP antibody is in a pharmaceutical composition at a pH of about 5.7-6.0. Most preferably, the anti-CGRP antibody is in a pharmaceutical composition at a pH of about 5.8.
In another particular embodiment the present invention provides a pharmaceutical formulation of the present invention for use in a method to treat or prevent chronic migraine in a patient in need by administering a monthly dose of 120 mg of an anti-CGRP antibody, wherein the anti-CGRP, wherein the anti-CGRP antibody is in the pharmaceutical composition. More preferably, the anti-CGRP antibody is in a pharmaceutical composition at a pH of about 5.7-6.0. Most preferably, the anti-CGRP antibody is in a pharmaceutical composition at a pH of about 5.8.
The present invention also provides a pharmaceutical formulation of the present invention for use in therapy, preferably for use in the treatment or prevention of migraines and/or headaches. In particular embodiments, the present invention provides a pharmaceutical formulation of the present invention for use in the treatment or prevention of at least one or more of the following conditions: episodic migraine, chronic migraine, episodic headaches, chronic headaches, chronic cluster headaches, and/or episodic cluster headaches. Preferably, the dose of anti-CGRP antibody that is administered to a patient is 120 mg or 240 mg for episodic and/or chronic migraine and 300 mg or 360 mg for episodic and/or chronic cluster headaches.
As used herein, the term "patient" refers to a human. In some embodiments, a patient is a human who has been diagnosed as having a condition or disorder for which treatment or administration with a pharmaceutical formulation of the present invention is indicated. In some embodiments, a patient is a human that is characterized as being at risk of a condition or disorder for which treatment or administration with a pharmaceutical formulation of the present invention is indicated.
As used herein, the term "treating" (or "treat" or "treatment") refers to processes involving a slowing, interrupting, arresting, controlling, stopping, reducing, or reversing the progression or severity of a symptom, disorder, condition, or disease, but does not necessarily involve a total elimination of all disease-related symptoms, conditions, or disorders associated with CGRP activity. As used herein, the term "prevention" (or "prevent" or "preventing") refers to precluding, averting, obviating, forestalling, reducing the incidence of, stopping, or hindering the symptoms of a disease, disorder and/or condition. Prevention includes administration to a subject who does not exhibit symptoms of a disease, disorder, and/or condition at the time of administration.
As used herein, the term "therapeutically effective amount" refers to the amount or dose of an anti-CGRP antibody in a pharmaceutical formulation of the present invention, which upon single or multiple dose administration to the patient, provides the desired pharmacological effect in the patient. A dose can include a higher initial loading dose, followed by a lower dose. A "dose" refers to a predetermined quantity of a therapeutic drug calculated to produce the desired therapeutic effect in a patient. A therapeutically effective amount can be determined by the attending diagnostician, as one skilled in the art, by considering a number of factors such as the patient's size, age, and general health, the specific disease or surgical procedure involved, the degree or severity of the disease or malady, the response of the individual patient, the mode of administration, the bioavailability characteristics of the preparation administered, the dose regimen selected, and the use of any concomitant medications.
As used herein, the term "month" or derivations thereof, refers to a time period that includes 28 to 31 consecutive days. The term "about" as used herein, means in reasonable vicinity of the stated numerical value, such as plus or minus 10% of the stated numerical value.
The general structure of an "antibody" is known in the art. Anti-CGRP antibodies are disclosed in WO2011/156324 . As used herein, a "drug substance" ("DS") is a formulation that comprises an antibody, buffer (e.g. histidine), excipient (e.g. NaCl), and surfactant (e.g. PS-80), and is within a certain pH range or at a specified pH. A "drug product" ("DP") is a formulation comprising a buffer, excipient, surfactant, and antibody, wherein the antibody in the DP may be at a lower concentration than the antibody concentration in the DS.
The pharmaceutical formulations of the present invention are in the liquid dosage form of a solution. Administration of the pharmaceutical formulations of the present invention may be via parenteral administration. Parenteral administration, as used herein, may include injection of a dosage form into the body by a sterile syringe or some other mechanical device such as an infusion pump. Parenteral routes can include intravenous, intramuscular, subcutaneous, and intraperitoneal routes of administration. Subcutaneous administration is a preferred route. The pharmaceutical formulations of the present invention are intended for pharmaceutical use in a human.
The invention is further illustrated by the following examples which should not be construed as limiting.
Antibodies of the invention can be made and purified as follows. An appropriate host cell, such as CHO, is either transiently or stably transfected with an expression system for secreting antibodies using an optimal predetermined HC:LC vector ratio or a single vector system encoding both LC and both HC, such as each LC being SEQ ID NO: 3 and each HC being SEQ ID NO: 4. Clarified media, into which the antibody has been secreted, is purified using any of many commonly-used techniques. For example, the medium may be conveniently applied to a Protein A or G Sepharose FF column that has been equilibrated with a compatible buffer, such as phosphate buffered saline (pH 7.4). The column is washed to remove nonspecific binding components. The bound antibody is eluted, for example, by pH gradient. Antibody fractions are detected, such as by SDS-PAGE, and then are pooled. Further purification is optional, depending on the intended use. The antibody may be concentrated and/or sterile filtered using common techniques. Soluble aggregate and multimers may be effectively removed by common techniques, including size exclusion, hydrophobic interaction, ion exchange, or hydroxyapatite chromatography. The purity of the antibody after these chromatography steps is greater than 99%. The product may be immediately frozen at -70°C in the formulation matrix of the invention or may be lyophilized. The amino acid and nucleic acid sequences for the exemplified antibody are provided below.
The manufacturing process for an anti-CGRP antibody pharmaceutical formulation of the present invention includes compounding of the buffer excipient composition, and adding the anti-CGRP antibody drug substance (DS).
The buffer excipient composition consists of L-Histidine, L-Histidine Hydrochloride Monohydrate, NaCl , PS-80, and water (Table 1). The anti-CGRP antibody comprises a light chain of SEQ ID NO: 3, and a heavy chain of SEQ ID NO: 4.
Table 1. Buffer excipient composition
Table 1. Buffer excipient composition
| 0.478 | 10 mM | |
| 1.45 | ||
| 8.76 | 150 mM | |
| 0.50 | 0.05% (w/v)* | |
| * weight per volume |
The buffer excipient composition is prepared and filtered. An appropriate quantity of water at a temperature not more than 25°C is weighed into a tared empty vessel of appropriate size. The appropriate quantities of L-Histidine, L-Histidine Hydrochloride Monohydrate and NaCl are added and mixed. PS-80 is weighed out in a glass container and an appropriate quantity of water is added into the glass container to give the indicated final concentration, and the solution is mixed. The PS-80 solution is added to the other excipients, the solution is mixed, and the solution is prepared to have a pH and osmolality adjusted to within 5.8 ± 0.3 and 254-344 mOsm/Kg, respectively. The buffer excipient composition is passed through a filter for bioburden reduction.
The anti-CGRP antibody DS is prepared by expressing the antibody in cells, purifying, concentrating, and freezing the antibody in solution in 10 mM histidine buffer, 150 mM NaC1, 0.05% PS-80, and pH of about 5.8. The DS solution is stored at -70°C. The frozen DS is equilibrated to a temperature of 20 ± 5°C and mixed with an appropriate amount of the buffer excipient solution to achieve the intermediate antibody DP concentration. The pH of the solution is checked to be within 5.8 ± 0.3.
The solution is mixed and a sample is taken for an in-process UV assay to determine the antibody DP concentration. An appropriate quantity of the buffer excipient solution is added to reach the final target batch weight. After mixing, the pH of the solution is checked to be within 5.8± 0.3. The antibody DP solution is passed through a filter for bioburden reduction prior to sterile filtration and filling into vials or syringes. The final concentration of the antibody DP can be between about 40 mg/mL to about 160 mg/mL.
Light can influence the active molecule in a drug formulation, as well as the final product or package resulting in photodegradation that may result in the loss of potency of the product. The effect of light on anti-CGRP antibody formulated in citrate buffer or histidine buffer at pH 5.8 in glass prefilled syringes is evaluated by size exclusion chromatography (SEC). The light exposure levels are approximately 20% of ICH Q1B for visible light and 10% for the UV light.
Anti-CGRP antibody, at approximately 165 mg/mL (in 10 mM Histidine, 150 mM NaCl, pH 6.0), is divided into two aliquots. One aliquot is dialyzed into 10mM histidine, 150mM NaCl, pH 5.8 buffer, and the other aliquot is dialyzed into 10mM citrate, 150mM NaCl, pH 5.8 buffer. Following dialysis, the antibody is diluted with the appropriate buffer (histidine or citrate) to 50 mg/mL or to 120 mg/mL. PS-80 is added to each formulation to a final concentration of 0.05%. The formulations are filtered through a 0.22 µm sterilizing grade PVDF filter and filled into glass prefilled syringes. Eight syringes per formulation for size exclusion chromatography (SEC) analysis are utilized. Syringes are placed in light chambers for exposure to either ultraviolet (UV), visible or both UV and visible light. Syringes in an opaque box are also included as "dark" controls. The temperature is constant at 20°C. Total polymer is measured by SEC. The results are summarized in Table 2.
Table 2. Comparison of percent total polymer between histidine and citrate buffer
| 1.44 | 1.70 |
| 1.63 | 2.06 |
| 1.88 | 2.60 |
| 2.33 | 3.47 |
| 1.54 | 1.98 |
| 2.18 | 2.89 |
| 2.38 | 3.66 |
| 2.86 | 4.20 |
Under conditions essentially as described above, the results provided in Table 2 demonstrate that the percent total polymer in histidine buffer were lower than that observed with citrate buffer. These data demonstrate that the formulations comprising the histidine buffer provide for better stability following exposure to light compared to formulations comprising citrate.
Stability of anti-CGRP antibody pharmaceutical formulations is evaluated in an excipient compatibility study. The formulations, at pH 6.0, comprise 120 mg/mL anti-CGRP antibody, 0.04% PS-80, either 10mM or 20mM histidine buffer, and either 150mM NaCl, 5% mannitol, or a combination of 100mM NaCl and 1.5% mannitol. Formulations are prepared by dialysis, and stored in HDPE containers at indicated temperatures, and are protected from light. Total polymer is determined by SEC at the beginning of the study, at 1 month, and at 2 months.
Table 3. Comparison of percent total polymer between mannitol, NaCl, and a combination of mannitol and NaCl.
| 10mM Histidine, 150mM NaCl | 0 | 1.53 | 1.53 | 1.53 |
| 1 | 1.68 | 2.02 | 2.43 | |
| 2 | 1.74 | 2.30 | 3.13 | |
| 20mM Histidine, 5% Mannitol | 0 | 1.98 | 1.98 | 1.98 |
| 1 | 2.09 | 2.37 | 2.60 | |
| 2 | 2.17 | 2.71 | 3.22 | |
| 10mM Histidine, 100mM NaCl, 1.5% Mannitol | 0 | 1.44 | 1.44 | 1.44 |
| 1 | 1.59 | 1.74 | 2.11 | |
| 2 | 1.56 | 2.09 | 2.84 |
Under conditions essentially as described above, the percent total polymer in the formulation comprising 5% mannitol was higher compared to the percent total polymer for the formulation comprising 150mM NaCl, or the formulation comprising 100mM NaCl and 1.5% mannitol. The addition of NaCl and/or a combination of NaCl and mannitol is shown to positively affect the stability of the protein.
Freezing is a common processing step used to maintain stability and quality of a protein during development and production, and may allow for a longer shelf life. However, freezing can induce complex physical and chemical changes in the solvent/solute conditions, resulting in denaturation of proteins with the possibility of generation of aggregates over time. The stability of pharmaceutical formulations in histidine buffer following freeze-thaw (FT) is determined by SEC. Eight different formulations are prepared and stored in HDPE containers. Each formulation is at pH 6.0, comprises 0.02% PS-80,10mM histidine, and either 150, 120, 100, or 20 mg/mL anti-CGRP antibody DP, and either 5% mannitol, 150mM NaCl, or 1.5% mannitol and 100mM NaCl.
Respective formulations in HDPE containers undergo three freeze-thaw cycles. For one cycle, each formulation is frozen at -70°C and thawed at room temperature. Respective formulations in HDPE containers undergo a slow freeze-thaw in a lyophilizer chamber. Controls are stored at 5°C for the duration of the study. Following the third cycle or following the slow freeze-thaw, percent total polymer is assessed by SEC.
Table 4. Comparison of percent total polymer between mannitol, NaCl, and a combination of mannitol and NaCl.
Table 4. Comparison of percent total polymer between mannitol, NaCl, and a combination of mannitol and NaCl.
| 120 mg/ml DP | 20 mg/ml DP | 150 mg/mL DP | 100 mg/mL DP | 20 mg/mL DP | 150 mg/mL DP | 100 mg/mL DP | 20 mg/mL DP | |
| 1.7 | 2.2 | 1.64 | 1.65 | 1.19 | 1.45 | 1.6 | 1.2 | |
| 1.8 | 2.8 | 1.58 | 1.65 | 1.71 | 1.57 | 1.51 | 1.28 | |
| N.D. | N.D. | 1.62 | 1.66 | 2.32 | 1.54 | 1.51 | 1.33 | |
| 1.8 | 5.1 | 1.6 | 1.61 | 3.15 | 1.51 | 1.5 | 1.29 | |
| 1.9 | 11.6 | 1.72 | 1.71 | 1.91 | 1.52 | 1.48 | N.D. | |
| N.D.: Not determined |
Under conditions described above, the percent total polymer in the formulation comprising 5% mannitol and 20 mg/mL DP was increased in FT cycle 3 and in the slow FT, compared to the percent total polymer in all other formulations. The percent polymer was also increased in the formulation comprising 20 mg/mL DP and 150mM NaCl. NaCl and/or a combination of NaCl and mannitol, together with concentrations of antibody greater than 20mg/mL in the formulation are shown to have a stabilizing effect on the protein following freeze-thaw.
The capillary shear device (CSD) is a high shear force simulating stress device that uses a peristaltic pump and a capillary tube to study physical stress on a formulated DP. A CSD is used to evaluate shear force physical stress of pharmaceutical formulations of the present invention, wherein said formulations comprise 10mM histidine, 150 mM NaCl, anti-CGRP antibody at a concentration of 5 mg/mL, 40 mg/mL, or 120 mg/mL, varying concentrations of PS-80, and pH of 6.0.
Anti-CGRP antibody DP is pumped through a 0.5mm inner diameter stainless steel capillary tube, with or without air, at a rate of approximately 3.3 mL/sec using a peristaltic pump. This pump rate results in a shear value of approximately 105 sec-1. Calculated energy dissipation is approximately 105 W/Kg. Controls do not undergo pumping.
Three different capillary shear device set-ups are utilized in this study. Stainless steel and PTFE capillary tubes are chosen because these materials are commonly used in manufacturing. Stainless steel capillary tubes without air in the system or PTFE capillary tubes without air in the system both represent a nominal stress condition. Nominal stress will be encountered when the solution is pumped using a peristaltic pump through a filling needle. Stainless steel capillary tubes with air entrapment in the system represent a high stress condition because the protein can unfold relatively easy in the air-liquid interface. Total polymer is determined by SEC, and particulate matter is determined by high accuracy particle counter (HIAC). SEC data are shown in Table 5, and HIAC data are shown in Table 6.
Table 5. Percent Total Polymer - SEC
Table 6. Particulate Matter - HIAC
| 0 | 0.89 | 0.91 | 1.65 |
| 0.005 | 1.04 | 1.03 | 1.63 |
| 0.02 | 1.06 | 1.06 | 1.13 |
| 0.03 | 1.09 | 1.06 | 1.12 |
| 0.05 | 1.17 | 1.19 | 1.23 |
| 0 | 1.23 | 1.23 | 2.49 |
| 0.005 | 1.24 | 1.24 | 1.35 |
| 0.02 | 1.30 | 1.25 | 1.47 |
| 0.03 | 1.31 | 1.30 | 1.52 |
| 0.05 | 1.31 | 1.38 | 1.50 |
| 0 | 1.58 | 1.61 | 1.86 |
| 0.005 | 1.48 | 1.66 | 1.66 |
| 0.02 | 1.48 | 1.68 | 1.68 |
| 0.03 | 1.49 | 1.65 | 1.59 |
| 0.05 | 1.51 | 1.75 | 1.65 |
| 0 | Control | 296 | 104 | 21 | 4 |
| 0.005 | Control | 53 | 26 | 11 | 6 |
| 0.02 | Control | 53 | 21 | 8 | 0 |
| 0.03 | Control | 57 | 19 | 6 | 1 |
| 0.05 | Control | 78 | 24 | 5 | 0 |
| 0 | Stainless Steel | 20284 | 1882 | 201 | 3 |
| 0.005 | Stainless Steel | 2612 | 501 | 94 | 4 |
| 0.02 | Stainless Steel | 1660 | 401 | 79 | 4 |
| 0.03 | Stainless Steel | 501 | 144 | 37 | 2 |
| 0.05 | Stainless Steel | 650 | 178 | 47 | 0 |
| 0 | Stainless Steel w/ Air | 62009 | 45330 | 24688 | 3683 |
| 0.005 | Stainless Steel w/ Air | 1225 | 344 | 162 | 2 |
| 0.02 | Stainless Steel w/ Air | 2993 | 803 | 178 | 4 |
| 0.03 | Stainless Steel w/ Air | 3959 | 946 | 135 | 0 |
| 0.05 | Stainless Steel w/ Air | 972 | 285 | 73 | 4 |
The SEC data in Table 5 show that under conditions essentially described above, the addition of PS-80 to the stainless steel with air groups (high stress conditions) led to a reduction in the total polymer.
Compared to formulations lacking PS-80, the addition of 0.005%, 0.02%, 0.03%, or 0.05% of PS-80 led to a reduction in particle formation in most of the groups as determined by HIAC (Table 6). These studies demonstrate that the addition of PS-80 to the solution reduces the particulate matter present in the anti-CGRP antibody formulation.
Formulations at pH 6.0 comprising the anti-CGRP antibody (120 mg/ml), 10mM histidine, 150mM NaCl, and 0.05% PS-80 are used to determine PS-80 oxidation at various temperatures and time-points. Respective formulations are filled into vials or glass prefilled syringes and placed in chambers at room temperature (at the beginning of the study), 5°C, 25°C, or 40°C. The corresponding buffer (10mM histidine, 150mM NaCl, 0.05% PS-80, pH 6.0) without the antibody is used as a control. PS-80 hydrolysis method is used to determine percent PS-80. Amount of free oleic acid and amount of total oleic acid are determined. PS-80 hydrolysis results in total oleic acid (TOA), and TOA is measured by high-performance liquid chromatography (HPLC). To obtain the percent of intact PS-80, free oleic acid is subtracted from the total oleic acid.
Table 7. Percent PS-80 in formulations at various time-points and temperatures
| 0 | RT | 0.051 | 0.052 | |
| 1 | 5°C | 0.052 | 0.05 | |
| 25°C | 0.054 | 0.051 | ||
| 40°C | 0.051 | 0.052 | ||
| 3 | 5C | 0.052 | 0.052 | |
| 25C | 0.054 | 0.051 | ||
| 6 | 5C | 0.054 | 0.051 | |
| 25C | 0.047 | 0.05 | ||
| 1 | 5C | 0.051 | 0.05 | |
| 25C | 0.048 | 0.051 | ||
| 40C | 0.029 | 0.05 | ||
| 3 | 5C | 0.052 | 0.051 | |
| 25C | 0.008 | 0.05 | ||
| 6 | 5C | 0.052 | 0.05 | |
| 25C | 0.006 | 0.038 |
Following a procedure essentially as described above, oxidation of PS-80 was most pronounced in the 2.25 mL control groups at 25°C at 3 and 6 months (Table 7). Oxidation of PS-80 was confirmed by mass spectrometry (data not shown).
In a similar study, formulations are prepared as indicated in Figure 1. DS is dialyzed into the respective matrix and PS-80 is added or diluted to achieve the indicated final concentration. Respective formulations are filled into glass prefilled syringes and stored in chambers at room temperature, 5°C, 25°C, 30°C, or 40°C. The concentration of PS-80 is determined at the beginning of the study at room temperature, after 1, 2, or 3 months at 5°C, 25°C, or 30°C, and at 6 months at 5°C or 25°C. The results are shown in Figure 1.
Following a procedure as essentially described above, oxidation of PS-80 was observed in formulations comprising 5 mg/mL antibody. These data show that antibody at a concentration greater than 5 mg/mL prevents oxidation of PS-80.
A phase IIb, randomized, double-blind, placebo-controlled, dose-ranging study was conducted with 410 patients aged 18-65 years with 4 to 14 migraine headache days and at least 2 migraine attacks per month. The patients were randomly assigned (2:1:1:1:1) to placebo or 1 of 4 LY2951742 dose groups. Subcutaneous injections of LY2951742 doses of 5 mg, 50 mg, 120 mg, 300 mg or placebo were given once every 28 days for 12 weeks. The primary objective was to assess whether at least one dose of LY2951742 was superior to placebo in the prevention of migraine headache. Superiority was defined as a ≥95% posterior probability of greater improvement for any LY2951742 dose compared with placebo, as measured by the mean change from baseline in the number of migraine headache days in the last 28-day period of the 12-week treatment phase.
The results showed that all 4 dose arms were numerically superior to placebo on primary outcome measures at all-time points. One dose arm (120 mg) of LY2951742 met the primary objective (p = 0.004) with a significantly greater reduction compared to placebo in the number of migraine headache days in the last 28 day period of the 12 week treatment phase.
A Phase III, randomized, double blind clinical trial is being conducted with 162 patients aged 18-65 years with at least two cluster periods lasting from 7 days to 1 year (when untreated) and separated by pain-free remission periods of ≥1 month. The patients are randomly assigned to either the placebo or treatment group. Subcutaneous injections of a pharmaceutical composition comprising LY2951742 at doses of 300 mg or placebo are given once every 30 days for 8 weeks. The primary objective is to assess whether 300 mg of LY2951742 was superior to placebo in the prevention of episodic cluster headaches. The primary outcome measured is the mean change from baseline in number of weekly cluster headache attacks after treatment.
- SEQ ID NO: 1 - Exemplified LCVR (of an anti-CGRP antibody of the present invention)
- SEQ ID NO: 2 - Exemplified HCVR (of an anti-CGRP antibody of the present invention)
- SEQ ID NO: 3 - Exemplified LC (of an anti-CGRP antibody of the present invention)
- SEQ ID NO: 4 - Exemplified HC (of an anti-CGRP antibody of the present invention)
- SEQ ID NO: 5 - Exemplified nucleotide sequence (encoding a LC of an anti-CGRP antibody of the present invention)
- SEQ ID NO: 6 - Exemplified nucleotide sequence (encoding a HC of an anti-CGRP antibody of the present invention)
- SEQ ID NO: 7 - Human αCGRP Peptide ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF
Claims (16)
- A pharmaceutical formulation comprising an anti-CGRP antibody at a concentration of 40 mg/mL to 160 mg/mL, histidine buffer at a concentration of 10 mM, NaCl at a concentration of 150 mM, PS-80 at a concentration of 0.05% (w/v), and a pH at 5.0 to 6.5, wherein the anti-CGRP antibody comprises a light chain (LC) and a heavy chain (HC), the amino acid sequence of LC given by SEQ ID NO: 3 and the amino acid sequence of HC given by SEQ ID NO: 4.
- The formulation of claim 1, wherein the anti-CGRP antibody comprises two LCs and two HCs, the amino acid sequence of each LC given by SEQ ID NO: 3 and the amino acid sequence of each HC given by SEQ ID NO: 4.
- The formulation of claim 1 or claim 2, wherein the concentration of anti-CGRP antibody is 50 mg/mL to 150 mg/mL.
- The formulation of claim 1 or claim 2, wherein the concentration of anti-CGRP antibody is 100 mg/mL to 160 mg/mL.
- The formulation of claim 1 or claim 2, wherein the concentration of anti-CGRP antibody is selected from the group consisting of 40 mg/mL, 50 mg/mL, 100 mg/mL, 120 mg/mL, and 150 mg/mL.
- The formulation of any one of claims 1 to 5, wherein the pH is 5.8.
- The formulation of any one of claims 1 to 3, wherein the concentration of anti-CGRP antibody is selected from the group consisting of 50 mg/mL, 100 mg/mL, 120 mg/mL, and 150 mg/mL, the concentration of histidine buffer is 10 mM, the concentration of NaCl is 150 mM, and the concentration of PS-80 is 0.05%, the pharmaceutical formulation having a pH between 5.5 to 6.0.
- The formulation of claim 7, wherein the said formulation is suitable for subcutaneous injection.
- A pharmaceutical formulation of any of claims 1 to 8 for use in the treatment or prevention of at least one of migraine, episodic headache, chronic headache, chronic cluster headache, and episodic cluster headache.
- The pharmaceutical formulation for use according to claim 9, wherein the dose of the anti-CGRP antibody administered to a patient is 300 mg.
- The pharmaceutical formulation for use according to claim 9, wherein the dose of the anti-CGRP antibody administered to a patient is 240 mg.
- The pharmaceutical formulation for use according to claim 9, wherein the dose of the anti-CGRP antibody administered to a patient is 120 mg.
- The pharmaceutical formulation for use according to any one of claims 10-12, wherein dose is administered at monthly intervals.
- The pharmaceutical formulation for use according to claim 11, wherein the 240 mg dose is followed by a monthly maintenance dose of 120 mg.
- A pharmaceutical formulation according to claim 1, comprising an anti-CGRP antibody at a concentration of 120 mg/mL, histidine buffer at a concentration of 10 mM, NaCl at a concentration of 150 mM, and PS-80 at a concentration of 0.05% (w/v), the pharmaceutical formulation having a pH between 5.0 to 6.5, wherein the anti-CGRP antibody comprises two LC and a two HC, the amino acid sequence of each LC given by SEQ ID NO: 3, and the amino acid sequence of each HC given by SEQ ID NO: 4.
- The pharmaceutical formulation according to claim 15, wherein the pharmaceutical formulation has a pH of 5.8.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562180905P | 2015-06-17 | 2015-06-17 | |
| US62/180,905 | 2015-06-17 | ||
| PCT/US2016/036407 WO2016205037A1 (en) | 2015-06-17 | 2016-06-08 | Anti-cgrp antibody formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1245813A1 HK1245813A1 (en) | 2018-08-31 |
| HK1245813B true HK1245813B (en) | 2024-11-29 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230159628A1 (en) | Anti-CGRP Antibody Formulation | |
| JP7329571B2 (en) | IL-2 pharmaceutical composition | |
| US20190328875A1 (en) | Etanercept formulations stabilized with meglumine | |
| HK1200709A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| JP2015519382A (en) | Pharmaceutical formulations for therapeutic antibodies | |
| US10485869B2 (en) | Etanercept formulations stabilized with meglumine | |
| EP4268803A1 (en) | Stable antibody preparation, preparation method for same, and applications thereof | |
| KR20180114018A (en) | Lyophilized pharmaceutical preparations and uses thereof | |
| JP2015038111A (en) | Liquid formulation of g-csf | |
| HK1245813B (en) | Anti-cgrp antibody formulation | |
| US20220265825A1 (en) | Opthalmic composition of bevacizumab | |
| WO2024020470A1 (en) | PHARMACEUTICAL SOLUTIONS OF ANTI-N3pGlu Aβ ANTIBODIES AND USES THEREOF | |
| HK40075622A (en) | Stable antibody preparation, and preparation method and use thereof | |
| CN120227455A (en) | Compositions containing antibodies that specifically bind to hepatitis B virus surface antigen (HBsAg) | |
| EA047938B1 (en) | OPHTHALMOLOGICAL COMPOSITION OF BEVACIZUMAB | |
| HK40115478A (en) | Aqueous formulations of an anti-cd22 antibody and uses thereof |